Agios Pharmaceuticals (AGIO) Q4 2024 earnings summary

Executive summary

• Achieved all key 2024 milestones, including regulatory filings for PYRUKYND (mitapivat) in thalassemia and completion of Phase 3 RISE UP enrollment for sickle cell disease.

• PYRUKYND expanded into larger patient populations, with strong Phase 3 results and anticipated launches in thalassemia (2025) and sickle cell disease (2026).

• Robust pipeline includes late, mid, and early-stage programs such as tebapivat and AG-236, targeting rare hematologic and metabolic diseases.

• Strong cash position of $1.5B at year-end 2024 supports independent execution, launches, and pipeline expansion.

• 2024 marked a transformative year, strengthening commercialization and financial position.

Financial highlights

• Q4 2024 PYRUKYND net revenue was $10.7M, up 51% year-over-year from $7.1M in Q4 2023 and 20% sequentially from Q3 2024.

• Full-year 2024 PYRUKYND net revenue reached $36.5M, a 36% increase over $26.8M in 2023.

• Net income for 2024 was $673.7M, compared to a net loss of $352.1M in 2023, driven by $1.1B in milestone and royalty payments.

• R&D expenses for Q4 2024 were $82.8M; full-year R&D was $301.3M, both slightly higher year-over-year.

• SG&A expenses for Q4 2024 were $51.7M; full-year SG&A was $156.8M, up 31% year-over-year, reflecting commercial launch preparations.

Outlook and guidance

• 2025 expected to be a breakout year, with focus on maximizing PYRUKYND's potential, expanding commercial reach, and progressing the pipeline.

• Anticipates FDA decision for PYRUKYND in thalassemia by September 7, 2025, with partial Q4 revenue due to access and payer setup lag.

• Expects topline results from Phase 3 RISE UP study in sickle cell disease in late 2025, with potential U.S. launch in 2026.

• Plans to file IND for AG-236 and complete enrollment in Phase 2b tebapivat study for LR-MDS in 2025.

• Continued disciplined cost management and capital allocation to support launches and pipeline advancement.